Program leadership for fighting antibiotic‑resistant Acinetobacter and Klebsiella infections
Core 1 Administrative Core
This project develops ways to better kill carbapenem‑resistant Acinetobacter and Klebsiella infections and to prevent those bacteria from becoming tolerant or resistant for patients facing these infections.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11164490 on NIH RePORTER |
What this research studies
This administrative core coordinates a team studying two dangerous, antibiotic‑resistant bacteria (CRAB and CRKP) to learn how they survive treatment and how drug combinations and dosing schedules can stop them. Researchers are studying bacterial tolerance (non‑replicating persisters), how penicillin‑binding proteins and resistance mechanisms change over time, and which antibiotic regimens produce the most bacterial killing. The group uses laboratory and animal models and works toward translating those findings into clinical dosing strategies and combination therapies. The core organizes resources, data sharing, and partnerships so the science can move more quickly toward helping patients.
Who could benefit from this research
Good fit: Patients with infections caused by carbapenem‑resistant Acinetobacter baumannii or carbapenem‑resistant Klebsiella pneumoniae, or those at high risk for these infections, would be most relevant to this project.
Not a fit: People with infections caused by other, non‑resistant bacteria or those not treated with antibiotics are unlikely to directly benefit from this work.
Why it matters
Potential benefit: If successful, this work could lead to better antibiotic combinations and dosing plans that clear resistant infections and reduce treatment failures.
How similar studies have performed: Previous laboratory and clinical work has shown that optimized antibiotic combinations and dosing can improve outcomes in resistant infections, while work specifically targeting tolerance/persister states and time‑dependent protein expression is a newer area.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Drusano, George Louis — University of Florida
- Study coordinator: Drusano, George Louis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.